ACTRN12621000033842招募中2 期
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1. The subject/legal guardian must be able to understand and sign the Human Research Ethics Committee-approved written Informed Consent Form (ICF) and privacy language as per national regulations (e.g., HREC and TGA requirement in Australia) prior to any study-related procedures being performed.
- •2. The subject is a male or female 18 to 70 years of age, inclusive
- •3. The subject must have a history of drug resistant epilepsy (as per the ILAE definition)
- •4. The subject must be taking 1 to 4 anti-epileptic drugs (AED) and must be on a stable dose of the AEDs for at least four (4) weeks prior to entering the 28-day screening period
- •5. If VNS implanted, the stimulation setting must have been stable for at least four weeks prior to entering the 28-day screening period
- •6. The subject/legal guardian must be able to use the seizure dairy to record seizure throughout the study
- •7. The subject must experience at least four (4) countable seizures within a 28-day period.
- •For continued enrollment into Treatment Period 1, each subject will be confirmed to have experienced at least four (4) countable seizures in the 28-day screening period
- •8. The subject must have interictal epileptiform discharges and/or seizure with an average frequency of approximately one (1) per hour on EEG recording.
- •For continued enrollment into Treatment Period 1, this will be confirmed by continuous 24-hour EEG performed during the 28-day screening period.
- •9. The subject is willing and able to comply with the study requirements
排除标准
- •1. Unwilling or inability to follow the procedures specified by the protocol
- •2. Pregnant or breast-feeding
- •3. Women of child-bearing potential and men who are unable or unwilling to take adequate contraceptive precautions, including one of the following:
- •o Hormonal contraception (birth control pills, injected hormones or vaginal ring)
- •o Intrauterine device
- •o Barrier methods (condom or diaphragm) combined with spermicide
- •o Surgical sterilization (hysterectomy, tubal ligation, or vasectomy)
- •4. Current treatment for another significant medical disorder, such as diabetes, heart disease or an untreated disorder, that is discovered during the 28-day screening period and might interfere with the study in the opinion of the Principal Investigator
- •5. An abnormality on clinical laboratory tests, physical examination, EEG or ECG that might increase the risks associated with trial participation or investigational product administration, such as hepatic enzyme elevation greater than twice normal and/or a GFR < 60 mL/min/1.73 m2
- •6. History (within last month) of illicit drug use or alcohol dependence, and a commitment not to take illicit drugs during the study
- •7. Concomitant treatment with more than four (4) AEDs
- •8. Evidence for a potentially progressive neurologic disorder, such as a brain tumor, multiple sclerosis or dementia
- •9. Planned epilepsy surgery within six months of enrollment
研究者
相似试验
已完成
2 期
Study of ZYN002 (transdermal gel) in Patients with Partial Onset SeizuresNeurological - EpilepsyEpilepsyACTRN12616000510448Zynerba Pharmaceuticals Pty Ltd210
已完成
2 期
Study of ZYN002 (transdermal gel) in Patients with Knee Pain due to OsteoarthritisMusculoskeletal - OsteoarthritisOsteoarthritisACTRN12616001104448Zynerba Pharmaceuticals Pty Ltd320
进行中（未招募）
1 期
Safety, Tolerability, and Pharmacodynamics of PF-05221304 in subjects with Nonalcoholic Fatty Liver Diseaseonalcoholic Fatty Liver Disease (NAFLD)MedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2017-001156-55-PLPfizer Inc. 235 East 42nd Street, New York, NY 10017305
进行中（未招募）
1 期
The purpose of this trial is to assess dose related safety, early efficacy, pharmacokinetics and pharmacodynamics of INT-787 in patients with severe alcohol-associated hepatitis (sAH).Severe Alcohol-Associated HepatitisMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871EUCTR2022-001639-10-FRIntercept Pharmaceuticals, Inc.50
进行中（未招募）
1 期
A Study of JNJ-38518168 in Symptomatic Adult Participants with Uncontrolled, Persistent AsthmaAsthmaMedDRA version: 17.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855EUCTR2012-004920-39-DEJanssen-Cilag International N.V.160